Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ling Pei

Showing results (161-170 of 217) with videos related to

Pageof 22
Sort By:
Blood|January 8, 2013
Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differencesFernando O Martinez, Laura Helming, Ronny Milde, et al.
JCI Insight|June 6, 2020
Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild diseaseYan Zhao, Ling Qin, Ping Zhang, et al.
Frontiers in Immunology|March 22, 2021
Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune PhenotypeEmily Fraser, Laura Denney, Agne Antanaviciute, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|March 20, 2026
Consortium-Based Patient and Public Involvement and Engagement for Long COVID Research: A Pirit-Focused Impact Evaluation of the PHOSP-COVID StudyLinzy Houchen-Wolloff, Joanna Bell, Rebecca Pritchard, et al.
JCI Insight|April 14, 2017
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenzaSuzanne L Cole, Jake Dunning, Wai Ling Kok, et al.
Trials|August 2, 2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trialTom Wilkinson, Rupert Dixon, Clive Page, et al.
The Lancet. Respiratory Medicine|December 19, 2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A Fisher, Tonny Veenith, Daniel Slade, et al.
Nature Biotechnology|August 28, 2012
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigensFrank Wegmann, Kate H Gartlan, Ali M Harandi, et al.
ERJ Open Research|October 23, 2023
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2Tom Wilkinson, Anthony De Soyza, Miles Carroll, et al.
The American Journal of Chinese Medicine|September 30, 2024
ERRATUM: Cytokine Storm in Acute Viral Respiratory Injury: Role of Qing-Fei-Pai-Du Decoction in Inhibiting the Infiltration of Neutrophils and Macrophages through TAK1/IKK/NF-κB PathwayXiao-Lan Ye, Sai-Sai Tian, Chen-Chen Tang, et al.
Pageof 22

Showing results (161-170 of 217) with videos related to

Sort By:
Pageof 22
Blood|January 8, 2013
Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differencesFernando O Martinez, Laura Helming, Ronny Milde, et al.
JCI Insight|June 6, 2020
Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild diseaseYan Zhao, Ling Qin, Ping Zhang, et al.
Frontiers in Immunology|March 22, 2021
Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune PhenotypeEmily Fraser, Laura Denney, Agne Antanaviciute, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|March 20, 2026
Consortium-Based Patient and Public Involvement and Engagement for Long COVID Research: A Pirit-Focused Impact Evaluation of the PHOSP-COVID StudyLinzy Houchen-Wolloff, Joanna Bell, Rebecca Pritchard, et al.
JCI Insight|April 14, 2017
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenzaSuzanne L Cole, Jake Dunning, Wai Ling Kok, et al.
Trials|August 2, 2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trialTom Wilkinson, Rupert Dixon, Clive Page, et al.
The Lancet. Respiratory Medicine|December 19, 2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A Fisher, Tonny Veenith, Daniel Slade, et al.
Nature Biotechnology|August 28, 2012
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigensFrank Wegmann, Kate H Gartlan, Ali M Harandi, et al.
ERJ Open Research|October 23, 2023
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2Tom Wilkinson, Anthony De Soyza, Miles Carroll, et al.
The American Journal of Chinese Medicine|September 30, 2024
ERRATUM: Cytokine Storm in Acute Viral Respiratory Injury: Role of Qing-Fei-Pai-Du Decoction in Inhibiting the Infiltration of Neutrophils and Macrophages through TAK1/IKK/NF-κB PathwayXiao-Lan Ye, Sai-Sai Tian, Chen-Chen Tang, et al.
Pageof 22